

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability											Traceability									
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(1) Sodium					67							67	64	96%								0
Samples and groups	[mmol/L]																					
Sample A		128	1,9	1,5	67	CVP	129	0,26	4%	123	135	67	65	97%								0
(2) Indirect ISE		128	1,8	1,4	52	0						52										
(3) Direct ISE		129	2,2	1,7	14	0						14										
Other					1	0						1										
						Ix 99																
Sample B		116	1,7	1,4	67	CVP	117	0,23	4%	112	122	67	65	97%								0
(2) Indirect ISE		116	1,5	1,3	52	0						52										
(3) Direct ISE		117	2,0	1,7	14	0						14										
Other					1	0						1										
						Ix 99																
(2) Potassium					67							67	67	100%								0
Samples and groups	[mmol/L]																					
Sample A		3,90	0,08	2,0	67	CVP	3,92	0,011	6%	3,68	4,16	67	67	100%								0
(2) Indirect ISE		3,91	0,08	2,2	52	0						52										
(3) Direct ISE		3,89	0,04	1,1	14	0						14										
Other					1	0						1										
						Ix 99																
Sample B		3,31	0,07	2,4	67	CVP	3,33	,0099	6%	3,13	3,53	67	67	100%								0
(2) Indirect ISE		3,32	0,07	2,4	52	0						52										
(3) Direct ISE		3,30	0,07	2,4	14	0						14										
Other					1	0						1										
						Ix 99																
(3) Chloride					67							67	67	100%								0
Samples and groups	[mmol/L]																					
Sample A		117	2,0	1,7	67	CVP	118	0,33	7%	109	127	67	67	100%								0
(3) Indirect ISE		118	1,8	1,5	52	0						52										
(4) Direct ISE		117	3,0	2,6	14	0						14										
Other					1	0						1										
						Ix 99																
Sample B		93,8	2,0	2,1	67	CVP	94,3	0,33	7%	87,6	101	67	67	100%								0
(3) Indirect ISE		93,8	2,0	2,1	52	0						52										
(4) Direct ISE		94,1	2,2	2,3	14	0						14										
Other					1	0						1										
						Ix 99																
(4) Calcium					62							62	58	94%								0
Samples and groups	[mmol/L]																					
Sample A		2,46	0,04	1,8	62	CVP	2,46	,0071	7%	2,28	2,64	62	62	100%								0
(2) Phot. with o-cresolftalexon		2,44	0,04	1,6	10	0						10										
(3) Photom. with arsenazo III		2,45	0,04	1,9	36	0						36										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability						Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(4) Calcium	[mmol/L]				62							62	58	94%									0	
Samples and groups																								
Sample A		2,46	0,04	1,8	62		CVP	2,46	,0071	7%	2,28	2,64		62	62	100%							0	
(4) Photomet. with NM-BAPTA		2,47	0,04	1,9	16	0								16										
Sample B		1,82	0,04	2,2	62		CVP	1,83	,0060	7%	1,7	1,96		62	58	94%							0	
(2) Phot. with o-cresolftalexon		1,79	0,04	2,4	10	0								10										
(3) Photom. with arsenazo III		1,83	0,03	1,9	36	0								36										
(4) Photomet. with NM-BAPTA		1,81	0,04	2,2	16	0								16										
(5) Inorganic phosphate	[mmol/L]				62									62	60	97%							0	
Samples and groups																								
Sample A		1,92	0,05	2,7	62		CVP	1,91	,0076	10%	1,71	2,11		62	61	98%							0	
(1) UV-molybdate method		1,92	0,05	2,7	57	0								57										
(2) Reduction photometry		1,95	0,06	3,4	5	0								5										
Sample B		1,51	0,03	2,4	62		CVP	1,51	,0057	10%	1,35	1,67		62	60	97%							0	
(1) UV-molybdate method		1,51	0,03	2,3	57	0								57										
(2) Reduction photometry		1,53	0,05	3,4	5	0								5										
(6) Iron	[µmol/L]				59									59	58	98%							0	
Samples and groups																								
Sample A		37,1	1,1	2,9	59		CVP	37,4	0,14	15%	31,7	43,1		59	59	100%							0	
(2) Method with ferrozine/ferene		37,3	1,1	2,9	36	0								36										
(4) Method with TPTZ		36,7	0,97	2,6	23	0								23										
Sample B		15,7	0,48	3,1	59		CVP	15,8	0,078	15%	13,4	18,2		59	58	98%							0	
(2) Method with ferrozine/ferene		15,7	0,43	2,7	36	0								36										
(4) Method with TPTZ		15,7	0,57	3,7	23	0								23										
(7) Magnesium	[mmol/L]				59									59	57	97%							0	
Samples and groups																								
Sample A		1,48	0,04	3,0	59		CVP	1,48	,0065	11%	1,31	1,65		59	58	98%							0	
(2) Photometry		1,48	0,04	3,0	57	0								57										
Other					2	0								2										
Sample B		1,20	0,04	3,4	59		CVP	1,19	,0054	11%	1,05	1,33		59	58	98%							0	
(2) Photometry		1,20	0,03	3,3	57	0								57										
Other					2	0								2										
(8) Lithium	[mmol/L]				8									8	7	88%							0	
Samples and groups																								
Sample A		1,80	0,06	3,7	8		CVP	1,75	0,030	12%	1,54	1,96		8	7	88%							0	
Other					8	0								8										
Sample B		1,02	0,07	7,1	8		CVP	0,997	0,019	12%	0,877	1,12		8	7	88%							0	
Other					8	0								8										
(9) Total protein	[g/L]				65									0								65	65	100%
Samples and groups																								
Sample A		48,5	1,5	3,0	65									0	CRV	48,79	0,58	9%	44,3	53,2		65	65	100%
(1) Biuret		48,5	1,5	3,0	65	0																		65
Sample B		55,5	1,5	2,7	65									0	CRV	55,54	0,66	9%	50,5	60,6		65	65	100%

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(27) gamma-GT					67							0									67	65	97%
Samples and groups	[µkat/L]																						
Sample A		3,61	0,13	3,6	67							0		CRV	3,702	0,098	15%	3,14	4,26	67	65	97%	
(1) IFCC method		3,61	0,13	3,6	67	0															67		
Sample B		1,65	0,06	3,9	67							0		CRV	1,724	0,043	15%	1,46	1,99	67	65	97%	
(1) IFCC method		1,65	0,06	3,9	67	0															67		
(28) LD					49							0									49	49	100%
Samples and groups	[µkat/L]																						
Sample A		3,78	0,14	3,8	49							0		CRV	3,806	0,087	18%	3,12	4,5	49	49	100%	
(3) IFCC method		3,78	0,14	3,8	49	0															49		
Sample B		6,50	0,21	3,2	49							0		CRV	6,463	0,14	18%	5,29	7,63	49	49	100%	
(3) IFCC method		6,50	0,21	3,2	49	0															49		
(29) Lipase					23							19	18	95%									0
Samples and groups	[µkat/L]																						
Sample A		4,41	0,99	22	23							19	18	95%									0
(0) Not specified; (58) Beckman Coulter (Olympus)		4,82	0,20	4,2	9	0	CVPG	4,78	0,084	24%	3,63	5,93	9										
(0) Not specified; (60) Roche		3,77	0,29	7,7	7	0	CVPG	3,71	0,21	24%	2,81	4,61	7										
Other					7	0							3										
Sample B		0,491	0,04	9,1	23							19	19	100%									0
(0) Not specified; (58) Beckman Coulter (Olympus)		0,480	0,03	6,2	9	0	CVPG	0,475	0,011	24%	0,361	0,589	9										
(0) Not specified; (60) Roche		0,485	0,02	4,6	7	0	CVPG	0,484	0,063	24%	0,367	0,601	7										
Other					7	0							3										
(30) Cholinesterase					26							25	25	100%									0
Samples and groups	[µkat/L]																						
Sample A		98,3	4,5	4,6	26							25	25	100%									0
(1) Standard method		98,0	4,2	4,3	25	0	CVP	100	1,1	12%	88	112	25										
Other					1	0							0										
Sample B		92,3	3,6	3,9	26							25	25	100%									0
(1) Standard method		92,0	3,4	3,7	25	0	CVP	94,2	0,92	12%	82,8	106	25										
Other					1	0							0										
(31) Albumin (elpho)					15							15	15	100%									0
Samples and groups	[-]																						
Sample A		0,626	0,05	8,1	15		CVP	0,648	0,085	15%	0,55	0,746	15	15	100%								0
(0) Not specified		0,626	0,05	8,1	15	0							15										
Sample B		0,604	0,04	7,1	15		CVP	0,626	0,080	15%	0,532	0,72	15	15	100%								0
(0) Not specified		0,604	0,04	7,1	15	0							15										
(32) gamma-globuline (elpho)					15							15	14	93%									0
Samples and groups	[-]																						
Sample A		0,132	0,02	16	15		CVP	0,122	0,035	30%	0,085	0,159	15	14	93%								0
(0) Not specified		0,132	0,02	16	15	0							15										
Sample B		0,144	0,01	13	15		CVP	0,136	0,033	30%	0,095	0,177	15	15	100%								0

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]						Comparability						Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(32) gamma-globuline (elpho)					15						15	14	93%							0			
Samples and groups	[-]																						
Sample B		0,144	0,01	13	15	CVP	0,136	0,033	30%	0,095	0,177	15	15	100%						0			
(0) Not specified		0,144	0,01	13	15							15											
(35) alpha-amylase pancreatic					12							12	12	100%						0			
Samples and groups	[µkat/L]																						
Sample A		2,84	0,07	2,6	12	CVP	2,88	0,028	10%	2,59	3,17	12	12	100%						0			
(1) With IFCC calibration		2,84	0,07	2,6	12							12											
Sample B		3,57	0,09	2,6	12	CVP	3,61	0,034	10%	3,24	3,98	12	12	100%						0			
(1) With IFCC calibration		3,57	0,09	2,6	12							12											
(36) Calcium ionised					8							8	8	100%						0			
Samples and groups	[mmol/L]																						
Sample A		1,61	0,09	6,0	8	CVP	1,62	0,021	10%	1,45	1,79	8	8	100%						0			
(2) Direct ISE		1,61	0,09	6,0	8							8											
Sample B		1,12	0,04	4,0	8	CVP	1,14	0,011	10%	1,02	1,26	8	8	100%						0			
(2) Direct ISE		1,12	0,04	4,0	8							8											

st_kn_np

End of report

Printed: 19.04.2019